Instil Bio Inc
TIL23.600USD
+1.370+6.16%
交易中 （美东）报价延迟15分钟
154.79M总市值
亏损市盈率 TTM
关于 Instil Bio Inc 公司
Instil Bio, Inc. 是一家临床阶段的生物制药公司，专注于开发一系列新型疗法。该公司寻求获得许可/收购和开发具有重大未满足医疗需求的疾病的新型治疗候选药物。其首个此类项目是用于治疗癌症的工程化肿瘤浸润淋巴细胞 (TIL) 细胞疗法。该公司正利用其共刺激抗原受体 (CoStAR) 平台开发一类新型基因工程 TIL 疗法。该公司的主要 CoStAR-TIL 候选产品 ITIL-306 表达一种 CoStAR 分子，旨在识别叶酸受体 α (Fra)，这是一种肿瘤相关抗原，在许多实体瘤中表达，包括卵巢癌、子宫癌、非小细胞肺癌和肾癌。CAR-T 和 TCR-T 疗法是由经过基因工程改造的 T 细胞组成的细胞产品，可识别肿瘤细胞表面的特定癌症相关抗原。
公司简介
公司代码TIL
公司名称Instil Bio Inc
上市日期Mar 19, 2021
CEOMr. Bronson Crouch
员工数量14
证券类型Ordinary Share
年结日Mar 19
公司地址3963 Maple Avenue
城市DALLAS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编75219
电话19724993350
网址https://instilbio.com/
公司代码TIL
上市日期Mar 19, 2021
CEOMr. Bronson Crouch
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Curative Ventures Management LLC
28.95%
Vivo Capital, LLC
8.93%
BML Capital Management LLC
6.35%
CPMG, Inc.
6.26%
Balyasny Asset Management LP
4.84%
Other
44.67%
持股股东
持股股东
占比
Curative Ventures Management LLC
28.95%
Vivo Capital, LLC
8.93%
BML Capital Management LLC
6.35%
CPMG, Inc.
6.26%
Balyasny Asset Management LP
4.84%
Other
44.67%
股东类型
持股股东
占比
Venture Capital
38.38%
Hedge Fund
18.62%
Investment Advisor
14.63%
Individual Investor
4.68%
Investment Advisor/Hedge Fund
4.61%
Research Firm
2.32%
Corporation
1.83%
Private Equity
1.78%
Pension Fund
0.34%
Other
12.81%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
139
5.72M
87.19%
-1.80M
2025Q1
177
6.10M
93.36%
-1.38M
2024Q4
187
6.08M
93.21%
-646.76K
2024Q3
221
6.16M
94.70%
+69.47K
2024Q2
217
4.68M
71.90%
-1.71M
2024Q1
222
4.70M
72.22%
-1.19M
2023Q4
226
4.39M
67.44%
-1.16M
2023Q3
227
4.47M
68.70%
-1.13M
2023Q2
230
4.57M
70.22%
-1.44M
2023Q1
241
4.80M
73.84%
-1.79M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Curative Ventures Management LLC
1.90M
28.95%
-1.00
-0.00%
Apr 02, 2025
Vivo Capital, LLC
585.49K
8.93%
--
--
Mar 31, 2025
BML Capital Management LLC
416.72K
6.35%
+16.72K
+4.18%
Mar 31, 2025
CPMG, Inc.
410.92K
6.26%
+1.00
+0.00%
Apr 02, 2025
Balyasny Asset Management LP
317.32K
4.84%
+255.69K
+414.86%
Mar 31, 2025
Millennium Management LLC
212.24K
3.24%
+158.99K
+298.56%
Mar 31, 2025
Invus Public Equities Advisors, LLC
203.93K
3.11%
+11.50K
+5.98%
Mar 31, 2025
The Vanguard Group, Inc.
168.10K
2.56%
+16.91K
+11.18%
Mar 31, 2025
Laumas (Sandeep)
160.00K
2.44%
--
--
Apr 02, 2025
Goldman Sachs & Company, Inc.
132.43K
2.02%
+5.50K
+4.34%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Tema Oncology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Micro-Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.01%
DFA Dimensional US Core Equity Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Tema Oncology ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
公告日期
类型
比率
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
